Alexopoulos Athanasios

Alexopoulos Athanasios Internist Oncologist

Education & Academic Qualifications

  • Graduated University of Athens Medical School


  • Clinical medical Oncologist, Internal Medicine, Clinical expertise in breast cancer liver and pancreatic cancer and all solid tumors.

Doctoral thesis

  • Doctoral Thesis: “Cancer Cachexia” University of Athens.

Fellowship in Societies, Membership in Journal Editorial Committees

  • Board member in Hellenic society of cancer research 

  • Board member of Hellenic society of clinical oncologists 

  • Hellenic Breast Cancer society 

  • ESMO

  • EORTC Breast Cooperative Group

  • Board member of Hellenic society of Psychosocial Oncology

  • Editorial board of medical edition “Hellenic Oncology”

Editorial Boards:

  • Editorial board of medical edition “Hellenic Oncology”


Work Experience

  • Liver Unit Kings College Hospital London 

  • Guys Hospital Clinical London Oncology and Breast Unit

  • Residencies and fellowships: 

  • Medical Oncologist in Saint Savvas Hospital for 27 years 

  • Medical Oncologist in Hygeia Hospital since 2007


Clinical & Research Interest

Clinical Interest:

  • Clinical interest in solid tumors with more interest in Breast Cancer

Research Interest:

  • Research interest in all areas of cancer care related to Breast Cancer, endometrial cancer, ovarian cancer, NCSLC, bladder cancer, liver, cholangiocarcinoma and pancreatic cancer.

  • My research is focused on prevention of Breast Cancer, prevention of recurrence after surgery, adjuvant treatment and treatment of recurrences. 


Recent Publications

  • Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast can-cer in Greece: An evaluation study Annals of Oncology 25 2014 and BMC Health Serv Res. 2015 Aug

  • A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines J Cancer Res Cin Oncol. 2010 Jan

  • Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER-2 positive recurrent breast cancer: find-ings from a case series Oncologie. 2005 Nov 

  • In vivo synergism between docetaxel and gemcitabine in patients with meta-static breast cancer: general concepts and future perspectives Semin Oncol. 2004 Apr 

  • Phase II sudy of pegylated liposomal doxorubicin (Caelyx) and docetaxel as first-line treatment in metastatic breast cancer Ann Oncol. 2004 Jun

  • Evidence for in vivo synergism between docetaxel and gemcitabine in pa-tients with metastatic breast cancer Ann Oncol. 2004 Jan

  • Gemcitabine plus irinotecan in breast cancer patients pretreated with tax-anes and anthracyclines: a multicenter phase II study Oncology. 2003

  • Salvage treatment of metastatic breast cancer with docetaxel and car-boplatin. A multicenter phase II trial Oncology. 2003

  • Docetaxel in combination with mitixantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study Ann Oncol. 2001 Jun

  • Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomized multicenter trial Lancet. 2001 May